6.29
-0.04(-0.63%)
Currency In USD
| Previous Close | 6.33 |
| Open | 6.63 |
| Day High | 6.68 |
| Day Low | 6.2 |
| 52-Week High | 37.5 |
| 52-Week Low | 3.81 |
| Volume | 65,899 |
| Average Volume | 56,953 |
| Market Cap | 10.34M |
| PE | -0.22 |
| EPS | -28.99 |
| Moving Average 50 Days | 7.47 |
| Moving Average 200 Days | 8.6 |
| Change | -0.04 |
If you invested $1000 in Lyra Therapeutics, Inc. (LYRA) since IPO date, it would be worth $6.78 as of September 13, 2025 at a share price of $6.29. Whereas If you bought $1000 worth of Lyra Therapeutics, Inc. (LYRA) shares 3 years ago, it would be worth $20.46 as of September 13, 2025 at a share price of $6.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
GlobeNewswire Inc.
Jun 02, 2025 11:00 AM GMT
ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN 2 trial also showed statistically significant improve
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improvements in both